Aghajanian C, et al. - Researchers assessed the efficacy and tolerability of incorporating three novel agents into initial therapy with paclitaxel and carboplatin (PC) in patients with chemotherapy-naïve stage III/IVA (with measurable disease) and stage IVB or recurrent (with or without measurable disease) endometrial cancer included in this randomized phase II trial. Three treatment arms comprised treatment with PC plus bevacizumab (Arm 1), PC plus temsirolimus (Arm 2) or ixabepilone and carboplatin (IC) plus bevacizumab (Arm 3). Comparable patients on the PC Arm of trial GOG209 were used as historical controls. Relative to historical controls, no significant increase in progression-free survival was found in any experimental arm. In Arm 1 but not in Arms 2 and 3, overall survival duration (with censoring at 36 months), was significantly increased when compared with controls. No new safety signals were identified.